Abstract
This randomized, single-blind, group-sequential trial evaluated the clinical efficacy and safety of α-Lipoic acid (ALA) in critically ill patients with COVID-19. Seventeen patients were enrolled and randomized to receive either 1200 mg/day of intravenous ALA plus standard care or a placebo plus standard care for 7 days. The primary outcome was the Sequential Organ Failure Assessment (SOFA) score, and the secondary outcome was 30-day all-cause mortality. Results indicated that the ALA group experienced a lower increase in SOFA scores and a reduced 30-day mortality rate (37.5% vs. 77.8%, p=0.09) compared to the placebo group. While limited by a small sample size, the findings suggest that ALA may mitigate organ dysfunction and improve survival in severe COVID-19 cases.
Introduction
In the early stages of the COVID-19 pandemic, clinicians identified "cytokine release syndrome" (CRS) and excessive production of reactive oxygen species (ROS) as primary drivers of severe disease. This systemic inflammatory response often leads to diffuse alveolar damage and multi-organ failure. α-Lipoic acid (ALA) is a potent antioxidant known to reduce systemic inflammation in conditions like acute coronary syndrome and organ transplantation. This study sought to determine if ALA could counteract the oxidative stress and inflammatory storm associated with SARS-CoV-2 to improve patient prognosis.
Methods
The trial was conducted at JinYinTan Hospital in Wuhan, China, between February and March 2020.
- Participants: 17 critically ill COVID-19 patients were enrolled.
- Intervention: Patients were randomized 1:1 to receive 1200 mg/day of ALA via intravenous infusion for 7 days or an equal volume of saline (placebo), both in addition to standard care.
- Blinding: The study was single-blind; outcome adjudicators were blinded to treatment assignments.
- Endpoints: The primary endpoint was the change in SOFA score over 7 days. The secondary endpoint was all-cause mortality at 30 days.
Results
Organ Failure Progression
At baseline, SOFA scores were similar between groups. Over the 7-day treatment period, the average SOFA score in the placebo group rose from 4.3 to 6.0 (a 1.7-point increase). In contrast, the ALA group remained relatively stable, with scores rising only from 3.8 to 4.0 (a 0.2-point increase). Although the trend favored the ALA group, the difference did not reach statistical significance (p=0.36) due to the small cohort.
Mortality and Safety
The 30-day all-cause mortality was notably lower in the ALA group (3/8 patients, 37.5%) compared to the placebo group (7/9 patients, 77.8%). This result achieved borderline statistical significance (p=0.09). Importantly, no unexpected drug-related adverse events were reported, indicating that high-dose IV ALA was well-tolerated in this critically ill population.
Discussion and Limitations
The findings suggest that ALA may stabilize organ function and potentially reduce mortality in critically ill COVID-19 patients by mitigating oxidative stress. However, the study's primary limitation is its extremely small sample size ($N=17$), which resulted from the successful control of the epidemic in Wuhan during the trial period. Additionally, the single-blind design and the potential for confounding secondary infections must be considered. While these results are promising, they serve as a signal for larger, multi-center clinical trials to validate the therapeutic role of ALA in severe viral pneumonia.
Summary updated